A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

NCT03114657 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

806

Enrollment

INDUSTRY

Sponsor class

Stopped This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.

Conditions

Alzheimer's Disease

Interventions

DRUG: Crenezumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche